Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6434797 | 0.87 | KDM1A (0.36) | SIGMAR1TMEM97ESR1ESR2KDM1A | |
| SCHEMBL6451400 | 0.83 | CHRNB2 (0.37) | SIGMAR1TMEM97CYP2D6SLC6A4 | |
| SCHEMBL6434353 | 0.77 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL6437602 | 0.66 | HRH3 (0.40) | SIGMAR1HRH3CYP2D6SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL4071422 | 0.64 | HTR6 (0.43) | SIGMAR1HRH3 | |
| Trifluoroacetic Acid SCHEMBL1018462 | 0.64 | HTR6 (0.43) | SIGMAR1HRH3 | |
| Trifluoroacetic Acid SCHEMBL6434348 | 0.62 | TYR (0.37) | ESR1ESR2KDM1A | |
| SCHEMBL4915480 | 0.61 | ADRA2A (0.46) | HRH3ESR1ESR2 | |
| SCHEMBL26343991 | 0.60 | ELANE (0.53) | ESR1ESR2 | |
| SCHEMBL11436506 | 0.60 | CYP3A4 (0.59) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1246300-C | Resorcinol derivatives | PFIZER (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| CN-1344250-A | Resorcinol derivatives | PFIZER (US) | 2002-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | SIGMAR1 3938/4885TMEM97 2855/4885HRH3 446/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | SIGMAR1 3938/4885TMEM97 2855/4885HRH3 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.